Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Pfizer: Steady As She Goes

After the restructuring of its operations, one key divestment, the acquisition of Hospira and some encouraging pipeline advances, Pfizer executives believe the company is on track for a return to significant growth in the future.

Read More »

Sanofi: Getting Back Into Growth

With new CEO Olivier Brandicourt at the helm, launches of new products in 2014 and 2015, pipeline progression, R&D collaborations and the reorganization of the company into a new structure coming in 2016, Sanofi is setting the stage for the future.

Read More »

Teva: The Path Not Taken

Snubbed by its initial takeover target Mylan, Teva moved on by acquiring Allergan’s generic business instead.

Read More »

Merck KGaA bets on cancer drugs to revitalize German firm

Merck KGaA is betting on its oncology pipeline to revitalize the German drugmaker as it sees falling sales from its best-selling medicine, multiple sclerosis treatment Rebif. Luciano Rossetti, head of global research and development at Merck’s biopharma business Merck Serono, said the company is in a “rapid evolution,” with up to 80 percent of its […]

Read More »

Eli Lilly, China-based Innovent Biologics Expand Cancer Drug Collaboration With $1 Billion PD-1 Pact

INDIANAPOLIS – Eli Lilly and Company (LLY) and Shanghai-based Innovent Biologics, Inc. have expanded their drug development collaboration to include three anti-PD-1 based bispecific antibodies for cancer treatments over the next decade, the company announced this morning.  The announcement expands on an existing deal between the two companies originally announced in March. The original deal to develop three cancer therapies could […]

Read More »

AstraZeneca pauses two lung cancer drug combination trials

AstraZeneca has temporarily halted two clinical trials combining experimental drugs to treat lung cancer, following reports of lung disease in some patients, the company said on Friday. The trials involve giving its drug AZD9291, which is currently awaiting regulatory approval, alongside the immune system-boosting medicine durvalumab, also known as MEDI4736, to treat patients with advanced […]

Read More »

Roche Snaps Up Bay Area’s Adheron in $580 Million Deal

Swiss-based Roche (RHHBY) acquired San Francisco-based Adheron Therapeutics for up to $580 million today.   Adheron focuses on technology that disrupts cell adhesion, which has potential applications for a variety of diseases. Its focus is Cadherin-11 (Cad-11), a surface protein found on fibroblasts in the skin and lungs, and fibroblast-like synoviocytes (FLS) found in the […]

Read More »

U.S. cancer doctors drop pricey drugs with little or no effect

U.S. oncologists, aware that patients are paying more of the costs of expensive cancer drugs, are increasingly declining to prescribe medicines that have scant or no effect, even as a last resort. At least half a dozen drugs, including colon cancer treatments Cyramza, from Eli Lilly & Co, and Stivarga, sold by Bayer AG, aren’t […]

Read More »

Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme’s Lemtrada in Clinical Trials

Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials – In the extension of two Phase III pivotal studies, 68 and 60 percent of Lemtrada-treated patients received no additional Lemtrada in the prior four years –– Consistent effects seen across relapse, […]

Read More »

Nobel discoveries on DNA repair now fueling cancer drug research

Cancer researchers are just beginning to understand the ramifications of the fundamental discoveries behind the 2015 Nobel Prizes in Chemistry, which were awarded on Wednesday to three scientists for explaining how cells repair mistakes in DNA that occur when cells divide. When deoxyribonucleic acid (DNA) repair mechanisms fail, they predispose people to cancer. That is […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom